XPG Inhibitors
XPG inhibitors constitute a diverse group of chemicals that exert their inhibitory effects on the XPG protein through various intricate biochemical pathways. These compounds strategically target key cellular signaling cascades to modulate the expression and function of XPG, a crucial player in nucleotide excision repair mechanisms. Nitidine chloride, for instance, indirectly inhibits XPG by impeding the translocation of NF-κB into the nucleus, thereby affecting the expression of genes involved in DNA repair. This disruption downregulates XPG function, compromising its role in maintaining genomic integrity.
Trametinib, a MEK inhibitor, attenuates the MAPK pathway, specifically inhibiting ERK1/2 phosphorylation. This interference hinders downstream activation crucial for XPG expression and function within the DNA repair processes. Additionally, compounds like Cisplatin induce XPG inhibition by forming DNA adducts, leading to the activation of p53-mediated pathways. This cascade modulates the expression and activity of XPG, impairing its function in nucleotide excision repair and compromising its efficacy in resolving DNA damage. Moreover, XPG inhibitors such as Wortmannin, a PI3K inhibitor, disrupt the PI3K-Akt pathway, influencing the expression and function of XPG in nucleotide excision repair processes. These compounds collectively showcase the intricate network of pathways targeted to inhibit XPG, providing a nuanced understanding of their mechanisms.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, attenuates the MAPK pathway, specifically inhibiting ERK1/2 phosphorylation. This disruption hinders the downstream activation of XPG, as ERK1/2 phosphorylation is crucial for XPG expression and function within the DNA repair processes. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin induces XPG inhibition by forming DNA adducts, leading to the activation of p53-mediated pathways. This triggers a cascade of events that modulate the expression and activity of XPG, impairing its function in nucleotide excision repair and rendering it less effective in DNA damage resolution. | ||||||
ETP-46464 | 1345675-02-6 | sc-497432 | 10 mg | $550.00 | ||
ATR inhibitors, such as ETP-46464, indirectly affect XPG by disrupting the ATR-Chk1 pathway. Inhibition of ATR leads to decreased phosphorylation of Chk1, influencing downstream signaling that regulates XPG expression and function, ultimately impeding the repair of DNA lesions. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin inhibits XPG through modulation of the Wnt/β-catenin pathway. By suppressing β-catenin signaling, curcumin alters the expression of genes involved in DNA repair, including XPG. This interference contributes to the inhibition of XPG-mediated nucleotide excision repair processes. | ||||||
Bleomycin | 11056-06-7 | sc-507293 | 5 mg | $275.00 | 5 | |
Bleomycin acts as an XPG inhibitor by inducing oxidative stress and DNA damage. This triggers a cascade of events involving the activation of p53 and other signaling pathways, leading to the downregulation of XPG expression and compromising its ability to effectively participate in DNA repair mechanisms. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187, a calcium ionophore, indirectly inhibits XPG by affecting the Ca2+/calmodulin-dependent protein kinase II (CaMKII) pathway. This disruption alters the phosphorylation status of proteins involved in DNA repair, including XPG, leading to impaired nucleotide excision repair and compromised genomic stability. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib inhibits XPG indirectly by targeting the PARP enzyme. As a PARP inhibitor, olaparib disrupts the repair of single-strand breaks, leading to the accumulation of DNA lesions. This indirectly affects XPG function, as the increased burden of unrepaired DNA compromises the overall efficiency of nucleotide excision repair. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly inhibits XPG by disrupting the PI3K-Akt pathway. Inhibition of PI3K impairs Akt signaling, influencing the expression and function of XPG in nucleotide excision repair processes, ultimately compromising the cell's ability to respond to DNA damage. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil inhibits XPG indirectly by interfering with the thymidylate synthase pathway. By inhibiting thymidylate synthase, it disrupts DNA synthesis and repair processes, leading to a decreased demand for XPG activity. This indirect inhibition compromises the overall efficiency of nucleotide excision repair. | ||||||
Topotecan Hydrochloride | 119413-54-6 | sc-204919 sc-204919A | 1 mg 5 mg | $45.00 $102.00 | 2 | |
Topotecan, a topoisomerase I inhibitor, indirectly inhibits XPG by inducing DNA damage. This triggers a cascade of events, including the activation of p53-mediated pathways, leading to the downregulation of XPG expression and compromising its function in nucleotide excision repair processes. | ||||||